ASE·Healthcare·$180M·#212 / 520 in Healthcare

STXS Stereotaxis, Inc.

48SPECULATIVE

CATEGORY BREAKDOWN

GROWTH1
QUALITY46
STABILITY59
VALUATION67
GOVERNANCE80

METRIC BREAKDOWN

Revenue Growth (YoY)

Year-over-year revenue growth rate

+0.5%
1

> 50% strong

Gross Margin

Revenue retained after direct costs

54.2%
76

> 50% strong

Cash Runway

Months of cash at current burn rate

17 months
62

> 24 months ideal

Debt / Equity

Total debt relative to shareholder equity

52.5%
53

< 25% strong

Price / Sales

Market cap relative to trailing revenue

5.5x
67

< 3x strong

Rule of 40

Growth rate plus operating margin

-91
0

> 40 excellent

Insider Ownership

Percentage of shares held by insiders

28.9%
98

> 20% strong

Share Dilution (12M)

Share count increase over last 12 months

+9.4%
44

< 5% ideal

5 more metrics available

Unlock all 8 metrics, score history, watchlist, and side-by-side comparison.

Try Free for 30 Days

AI ANALYSIS REPORT

AI-GENERATED

BUSINESS SUMMARY

Stereotaxis, Inc. (STXS) is a healthcare company trading on ASE with a market capitalization of $180M. The company currently carries a SPECULATIVE rating of 48/100, suggesting a mixed fundamental profile with both strengths and weaknesses. The fundamental profile shows modest single-digit revenue growth at 0.5% year-over-year, paired with healthy gross margins at 54.2%. The balance sheet shows elevated leverage that warrants monitoring, and the company has moderate cash runway of about 1 year.

VERDICT

STXS scores 48/100 — a mixed profile with some promising metrics alongside notable weaknesses. This is a higher-risk, higher-reward proposition that depends heavily on execution. This report is based on the latest available financial data and is intended as a starting point for research, not a buy or sell recommendation.

MARKET OPPORTUNITY

In the healthcare sector, cash runway and pipeline progress are critical metrics. Revenue quality depends on whether income comes from product sales, partnerships, or milestones. Stereotaxis, Inc. operates with strong insider ownership of 28.9%, indicating significant skin in the game, which provides a signal about management's confidence in the company's direction. At a market cap of $180M, the company is moderately valued on a price-to-sales basis at 5.5x P/S. The combination of these factors positions STXS as a higher-risk position that requires careful due diligence before considering an investment.

REVENUE QUALITY

Revenue growth stands at 0.5% year-over-year, which is in line with the typical small-cap growth rate. Gross margins of 54.2% are adequate for the sector but leave room for operational leverage as the company scales. The Rule of 40 score of -91 is well below the benchmark, indicating challenges in both growth and profitability. Cash runway of 17 months is adequate but should be monitored.

COMPETITIVE ADVANTAGE

Evaluating Stereotaxis, Inc.'s competitive position requires looking beyond the numbers. The 28.9% insider ownership is a strong positive signal — when management has significant personal wealth tied to the company, decisions tend to favor long-term value creation over short-term metrics. The margin structure suggests the company operates in a competitive market where differentiation is harder to maintain. Share count management has been reasonable. Investors should research the specific sources of competitive advantage — patents, customer switching costs, scale economies, or brand — that could protect margins over time.

GROWTH THESIS

STXS presents a speculative fundamental profile that requires a specific thesis to justify investment. Key catalysts to watch include: revenue growth trajectory over the next 2-3 quarters, margin expansion or contraction, and any changes in insider buying or selling activity.

KEY RISKS

Execution risk is significant — many small-cap companies in this sector fail to transition from growth to profitability. The elevated debt-to-equity ratio of 53x increases financial risk and limits the company's flexibility to weather downturns or invest in growth. Limited cash runway of 17 months means the company may need to raise capital, potentially diluting existing shareholders. Small-cap stocks carry inherently higher risk than large-caps, including limited analyst coverage, lower institutional ownership, and higher sensitivity to market downturns. Always conduct thorough due diligence beyond quantitative metrics.

Full AI Report available

Unlock the complete analysis including market opportunity, revenue quality, competitive moat, growth thesis, and risk assessment.

Try Free for 30 Days

Report generated: Mar 26, 2026

SCORE HISTORY

Track how this score changes over time. Start your free trial to see the full score trend chart.

SCORE ALERT

Get notified when STXS's score changes by 5+ points.

DATA INFO

Last updated: Mar 11, 2026

Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.